Vmbook Online ordering

Biotechnology

Repros Therapeutics Inc. was a clinical-stage biopharmaceutical company, which focuses on the development of new drugs for hormone-related diseases and disorders. The company was founded in 1987 and was listed on the NASDAQ stock exchange under the ticker symbol "RPRX." Unfortunately, the company has since been acquired by another company, and as of April 2022, it is no longer trading.

However, I can provide general information about the company's history, products, and financial performance.

History:

Repros Therapeutics was founded in 1987 with a focus on developing drugs that could treat hormone-related diseases and disorders. Their major drug candidates were focused on treating conditions such as hypogonadism, a condition where the body does not produce enough testosterone.

Products:

Repros' most advanced drug candidate was Androxal, a once-daily oral treatment for hypogonadism. The company completed enrolling patients for its Phase 3 clinical trail for Androxal in June 2012, but unfortunately, the drug failed its Phase III clinical trial. The company also had a second drug candidate, Proellex, an oral medication for the treatment of uterine fibroids, but the development of the drug was discontinued.

Financial Performance:

Repros Therapeutics, just like any development-stage biotechnology company, had experienced its ups and down financially. The company had several public offerings of its common stock to raise capital, which helped fund its clinical trials and other operations. However, the company faced significant challenges in bringing its drug candidates to market, which impacted its financial performance.

In the first quarter of 2018, Repros Therapeutics reported a net loss of $2.5 million, or $(0.22) per share, compared to a net loss of $3.5 million, or $(0.35) per share, for the same period in 2017. At the end of 2018, the company had cash and cash equivalents of $24.8 million.

On April 25, 2018, Repros Therapeutics announced that it had entered into a definitive merger agreement with Public II, Inc., a publicly traded special-purpose acquisition company. Under the agreement terms, Public II, Inc. would acquire Repros Therapeutics, and the combined company would operate under the name of Repros Therapeutics, Inc.

However, as mentioned earlier, Repros Therapeutics is no longer trading, and further information about the company's financials is unavailable.